Searched over 200M research papers
6 papers analyzed
These studies suggest lisinopril has a slower onset of action compared to other antihypertensive agents like captopril and enalapril.
20 papers analyzed
Lisinopril is a nonsulfhydryl angiotensin-converting enzyme (ACE) inhibitor widely used for treating hypertension and congestive heart failure (CHF). Unlike some other ACE inhibitors, lisinopril does not require biotransformation for its pharmacological activity, making it effective immediately upon absorption. This article delves into the onset of action of lisinopril, supported by various research findings.
Lisinopril begins to exert its antihypertensive effects within 1 to 2 hours after oral administration. This rapid onset is crucial for managing acute hypertensive episodes . Peak serum concentrations of lisinopril are typically observed between 6 to 8 hours post-dosing, which aligns with the time it takes to achieve maximum blood pressure reduction.
In comparative studies, lisinopril has shown a slower onset of action compared to captopril but a more sustained effect. For instance, while captopril reaches its peak effect within 30 to 40 minutes, lisinopril continues to lower plasma ACE and angiotensin II levels progressively, reaching its lowest values around 6 hours after administration. This gradual and sustained action can be clinically valuable for long-term blood pressure management.
One of the significant advantages of lisinopril is its prolonged duration of action, which allows for once-daily dosing. The antihypertensive effects of lisinopril persist for at least 24 hours, making it a convenient option for patients . This extended duration is particularly beneficial compared to other ACE inhibitors like captopril, which may require dosing every 8 to 12 hours, or enalapril, which might necessitate twice-daily dosing.
Lisinopril reaches a steady state within 2 to 3 days of consistent dosing, with minimal accumulation in patients with normal renal function. However, significant accumulation can occur in patients with severe renal impairment, necessitating dose adjustments.
Lisinopril has been demonstrated to be as effective as other antihypertensive agents, such as hydrochlorothiazide, nifedipine, and beta-blockers, in treating essential hypertension. It also shows comparable efficacy to captopril in managing CHF. The smooth and gradual reduction in blood pressure without affecting heart rate or cardiovascular reflexes makes lisinopril a preferred choice for many clinicians.
Common side effects of lisinopril include dizziness and cough, with less frequent reports of rash and proteinuria. Potential interactions with diuretics, potassium supplements, and nonsteroidal anti-inflammatory drugs (NSAIDs) should be monitored.
Lisinopril is a potent ACE inhibitor with a rapid onset of action within 1 to 2 hours and a prolonged duration of effect lasting at least 24 hours. Its efficacy in treating hypertension and CHF, combined with a favorable safety profile and convenient once-daily dosing, makes it a valuable therapeutic option. Further research may continue to elucidate its comparative advantages over other ACE inhibitors in specific patient populations.
Most relevant research papers on this topic